{"filings":[{"id":834000,"accession_number":"0001297184-26-000038","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2026-06-03T20:15:45+00:00","items":["5.07"],"status":"ready","headline":"Amphastar shareholders elect three directors, ratify EY, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All three Class I nominees elected: Gaugh 35.2M for, Peters 23.6M for, Liawatidewi 23.2M for.","Peters and Liawatidewi each received over 11.7M against votes.","Ratification of Ernst & Young as auditor for FY2026 passed 39.2M to 0.7M.","Advisory say-on-pay approved 32.6M for; frequency set at 1 year with 33.8M votes.","All proposals passed with broker non-votes of 4.4M on director and advisory items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91979,"accession_number":"0001297184-26-000031","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q1 2026 GAAP net income drops 75% to $6.4M; adjusted EPS falls to $0.42","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues flat at $171.2M vs $170.5M YoY.","GAAP net income $6.4M ($0.14 diluted EPS) vs $25.3M ($0.51) in Q1 2025.","Adjusted non-GAAP net income $19.5M ($0.42 diluted EPS) vs $36.9M ($0.74).","Launched Ipratropium Bromide HFA; signed license for synthetic corticotropin compound."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":171171000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102428,"accession_number":"0001104659-26-027814","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Amphastar Board authorizes $50M increase to share buyback program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized $50M increase to buyback program on March 12, 2026.","Program has indefinite duration; primary goal is offsetting dilution from equity compensation.","Purchases may be via open market, block trades, Rule 10b5-1 plans, or private transactions.","Timing and number of shares depend on price, regulatory requirements, and other conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102427,"accession_number":"0001297184-26-000015","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Amphastar enters employment agreements with two executives; base salaries $525,800 and $590,000","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jacob Liawatidewi (EVP of Corp Admin) base salary $525,800, target bonus 55%.","Rong Zhou (Sr EVP of Production) base salary $590,000, target bonus 53%.","Severance: 2x (base + avg bonus) outside CIC; 4x during CIC period.","Full equity acceleration on qualifying termination or change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102426,"accession_number":"0001297184-26-000013","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Amphastar enters supply agreement with related party Letop, amends contract with Hanxin","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Supply agreement with Nanjing Letop (Henry Zhang, son of CEO); no minimum purchase, 5-year term.","Contract Research Amendment shifts work from AMP-107 to AMP-105; total cost increased by ~$0.6M.","Both transactions are related-party and approved by Audit Committee; deemed not material.","Payments under supply agreement will be made in Chinese yuan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102425,"accession_number":"0001297184-26-000007","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q4 revenue $183.1M, down 1.8% YoY; GAAP EPS $0.51 vs $0.74","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2025 net revenue $719.9M, down 1.6% YoY from $732.0M.","GAAP net income Q4 $24.4M ($0.51 diluted EPS) vs $38.0M ($0.74) in Q4 2024; FY $98.1M ($2.03) vs $159.5M ($3.06).","Adjusted non-GAAP net income Q4 $34.2M ($0.73 diluted EPS) vs $47.2M ($0.92) a year ago.","CEO cites BAQSIMI double-digit growth and FDA approvals of iron sucrose and teriparatide injections as positives.","Three novel peptides and a synthetic corticotropin compound added to pipeline for oncology, ophthalmology, and immunology."],"consensus_eps_estimate":null,"consensus_eps_actual":2.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":719887000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102424,"accession_number":"0001297184-26-000002","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Amphastar Licenses Synthetic Corticotropin (AMP-110) from Hanxin in Exclusive US/Canada Deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amphastar gained exclusive rights to develop and commercialize AMP-110 (synthetic ACTH) in the US and Canada from Nanjing Hanxin.","Upfront payment of $2 million; potential milestones up to $14 million (development) and $75 million (sales).","Royalty payments capped at $7.5 million per year and $60 million total; Hanxin will also pay Amphastar royalties on certain sales.","Related-party transaction: CEO Jack Zhang and Chairman Mary Luo beneficially own a majority of Hanxin.","US ACTH market exceeded $684 million in 2024; AMP-110 aims for inflammatory and autoimmune conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118697,"accession_number":"0001297184-25-000062","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q3 net income drops 57% YoY to $17.4M; adjusted EPS $0.93 vs $0.96","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues of $191.8M, flat YoY vs $191.2M.","GAAP net income of $17.4M ($0.37 diluted EPS) vs $40.4M ($0.78) in Q3 2024.","Adjusted non-GAAP net income $44.7M ($0.93 diluted EPS) vs $49.6M ($0.96).","BAQSIMI revenue grew 14% YoY; FDA approval and launch of iron sucrose injection noted.","Nine-month 2025 GAAP net income $73.7M ($1.52 EPS) vs $121.6M ($2.32) prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":536782000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118696,"accession_number":"0001297184-25-000058","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Amphastar enters exclusive BAQSIMI distribution deal for Greater China with related party","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive distributor Chengong will market BAQSIMI in Mainland China, Taiwan, Hong Kong, Macau.","Chengong must obtain regulatory approvals and conduct post-marketing clinical trials.","10-year term; minimum purchase amounts per contract year; profit sharing above floor price.","Related party: CEO Jack Zhang and Chairman Mary Luo family own majority of Chengong's parent Hanxin.","Audit Committee approved the deal; total revenue over 10 years not yet determinable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135210,"accession_number":"0001297184-25-000054","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Amphastar enters $2.8M R&D agreement with related-party Hanxin for AMP-107 cell banks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Nanjing Hanxin to develop Recombinant Peptide Research Cell Banks (RCBs) for product candidate AMP-107.","Total cost not to exceed ~$2.8M; initial payment ~$0.3M; payments in Chinese yuan.","Hanxin majority-owned by CEO Jack Zhang, Chairman Mary Luo, and family; approved by independent audit committee.","Term of three years; all title to RCBs and related IP will belong to Amphastar."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135209,"accession_number":"0001558370-25-011134","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Amphastar licenses three novel peptides from Anji for up to $453M total","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exclusive license for three proprietary peptides targeting oncology and ophthalmology in U.S. and Canada.","First asset: endogenous peptide suppressing multiple cancer types; second: novel peptide-docetaxel conjugate; third: topical VEGFR eye drop for wet AMD.","Upfront $6M ($0.75M earnest + $5.25M), development milestones up to $42M, sales milestones up to $225M, royalties capped at $60M per product.","Anji receives non-exclusive license outside territory; pays Amphastar low single-digit royalties on certain net sales.","Term: 10 years from first commercial sale per product; Amphastar can extend up to additional 10 years or patent expiry."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135208,"accession_number":"0001297184-25-000048","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q2 2025 revenue $174.4M, GAAP EPS $0.64; BAQSIMI sales up 21%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $174.4M vs $182.4M YoY; GAAP net income $31.0M ($0.64 diluted EPS).","Adjusted non-GAAP net income $40.9M ($0.85 diluted EPS) vs $48.7M ($0.94) YoY.","BAQSIMI sales increased 21% YoY, cited as key revenue driver.","Announced multi-year plan to quadruple manufacturing capacity at Rancho Cucamonga HQ."],"consensus_eps_estimate":null,"consensus_eps_actual":1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":344942000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135207,"accession_number":"0001297184-25-000040","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Amphastar appoints David Gaugh as Class I director; board size increased to 11","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased authorized directors from 10 to 11 and appointed David Gaugh effective July 18, 2025.","Gaugh will serve until the 2026 annual meeting; no committee assignments at this time.","Initial compensation: $260,000 aggregate grant date fair value, 50% RSUs and 50% stock options, vesting on first anniversary.","Board determined Gaugh is independent under Nasdaq listing standards; no reportable transactions or arrangements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152181,"accession_number":"0001297184-25-000036","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Stockholders approve charter amendments for officer exculpation and forum selection removal at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected three Class III directors: Jack Y. Zhang, Richard Prins, Diane G. Gerst (each with majority support).","Approved charter amendment for officer exculpation under Delaware law (35.5M for, 2.9M against).","Approved removal of forum selection provision from charter (37.4M for, 52k against).","Ratified Ernst & Young as independent auditor for fiscal 2025 (41.5M for).","Bylaws amended to specify Delaware Court of Chancery as exclusive forum for certain internal actions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152180,"accession_number":"0001297184-25-000025","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q1 2025 GAAP net income $25.3M ($0.51 EPS); adjusted EPS $0.74","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $170.5M, down from $171.8M in Q1 2024.","GAAP net income $25.3M ($0.51 diluted EPS) vs $43.2M ($0.81) last year.","Adjusted non-GAAP net income $36.9M ($0.74 EPS) vs $55.3M ($1.04) prior year.","CEO cites BAQSIMI and Primatene MIST growth; FDA accepted insulin biosimilar AMP-004 application.","Company managing resources for efficient operations amid revenue decline."],"consensus_eps_estimate":null,"consensus_eps_actual":0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":170528000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171011,"accession_number":"0001297184-25-000003","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q4 net revenue $186.5M, adj EPS $0.92; FY $732M, adj EPS $3.86","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenue $186.5M, up 4.7% YoY; GAAP net income $38.0M ($0.74 per share).","FY 2024 net revenue $732.0M, up 13.6% YoY; GAAP net income $159.5M ($3.06 per share).","Adjusted non-GAAP net income Q4 $47.2M ($0.92 per share); FY $200.8M ($3.86 per share).","Primatene MIST exceeded $100M annual sales in 2024; BAQSIMI factory sales grew 12% vs Q4 2023.","CEO cites progress on proprietary pipeline for 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":3.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":731967000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187987,"accession_number":"0001297184-24-000055","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q3 2024 revenue up 5.9% to $191.2M; adjusted EPS down to $0.96","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $191.2M vs $180.6M in Q3 2023, up 5.9%.","GAAP net income $40.4M ($0.78 diluted EPS) vs $49.2M ($0.91) year ago.","Adjusted non-GAAP net income $49.6M ($0.96 diluted EPS) vs $61.9M ($1.15).","Growth driven by BAQSIMI and Primatene MIST; Primatene on track for $100M annual sales.","No updated guidance provided in the release."],"consensus_eps_estimate":null,"consensus_eps_actual":2.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":545444000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204490,"accession_number":"0001297184-24-000051","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Amphastar subsidiary enters exclusive Primatene MIST distribution deal for Greater China; est. $10M over 10 yrs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Armstrong (Amphastar subsidiary) appoints Genreach as exclusive distributor for Primatene MIST in Mainland China, Taiwan, Hong Kong, Macau; 10-year term.","Estimated total revenue to Amphastar over 10 years is ~$10 million, subject to currency exchange adjustments.","Genreach is responsible for obtaining all regulatory approvals in the region.","Related-party transaction: CEO Jack Zhang and Chairman Mary Luo beneficially own majority of Hanxin, Genreach's parent.","Minimum purchase amounts per contract year; profit sharing based on Genreach's per unit net revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204489,"accession_number":"0001297184-24-000045","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q2 revenue $182.4M, adjusted EPS $0.94; both up ~25-45% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $182.4M (Q2) vs $145.7M YoY; six-month $354.2M vs $285.7M.","GAAP net income $37.9M ($0.73 diluted EPS) vs $26.1M ($0.49) YoY.","Adjusted non-GAAP net income $48.7M ($0.94 diluted EPS) vs $34.8M ($0.65) YoY.","CEO highlighted BAQSIMI as a leading portfolio driver amid transition to branded/biosimilar products."],"consensus_eps_estimate":null,"consensus_eps_actual":1.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":354230000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221290,"accession_number":"0001297184-24-000042","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Amphastar board authorizes $50M increase to share buyback program to offset dilution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$50M increase to buyback program authorized June 3, 2024; program continues indefinitely.","Primary goal is to offset dilution from equity compensation programs.","Purchases may be via open market, block trades, Rule 10b5-1 plans, or negotiated transactions.","Timing and number of shares repurchased depend on price, corporate and regulatory factors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221289,"accession_number":"0001297184-24-000033","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q1 2024 net revenue $171.8M, GAAP EPS $0.81, adjusted EPS $1.04","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues of $171.8M vs $140.0M in Q1 2023, up 23% YoY.","GAAP net income $43.2M ($0.81 dil EPS) vs $26.0M ($0.50) a year ago.","Adjusted non-GAAP net income $55.3M ($1.04 dil EPS) vs $32.1M ($0.62) YoY.","BAQSIMI revenue grew 22% over Eli Lilly's reported Q1 2023 revenue.","No forward guidance provided in the release."],"consensus_eps_estimate":null,"consensus_eps_actual":0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":171836000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}